Clinical trials: Cancer of the Prostate
Prostate Cancer, Venous Thromboembolism
PREvention of VENous ThromboEmbolism Following Radical Prostatectomy
The PREVENTER Trial aims to compare the use of perioperative pharmacologic prophylaxis (subcutaneous heparin) with intermittent pneumatic compression devices (IPCs) to the use of IPCs alone for the prevention of venous…
- Conditions
- Prostate Cancer, Venous Thromboembolism, Lymphocele After Surgical Procedure, Deep Venous Thrombosis
- Trial name
- PREVENTER (NCT03006562)
- Testing
- Subcutaneous Heparin
- Where
- United States
- Volunteers
- 501 people
- Sponsor
- Johns Hopkins University
Prostate Carcinoma
68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer
This clinical trial studies the use of gallium-68 (68Ga)-DOTA-Bombesin as the imaging agent for positron emission tomography (PET)/magnetic resonance imaging (MRI), collectively PET-MRI, in patients with prostate cancer.
- Trial name
- NCT02440308
- Testing
- 68Ga-DOTA-Bombesin, Magnetic Resonance Imaging (MRI) scan, Positron Emission Tomography (PET) scan
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Prostate Cancer
Metformin for Rising PSA Remote Trial
Clinical trials are critical to informing the care of patients with cancer. However, only 3-5% of patients with cancer enroll in clinical trials.
- Trial name
- M-RePoRT (NCT02376166)
- Testing
- Metformin
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Matthew Galsky
Prostate Cancer
Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer
This was a Phase 1, open-label, fixed-dose study of immunization with the NY-ESO-1 protein combined with CpG 7909 as an adjuvant in patients with histopathologically confirmed, high-risk Stage D1 or advanced prostate cancer.
- Trial name
- NCT00292045
- Testing
- NY-ESO-1 protein/CpG 7909
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 15 people
- Sponsor
- Ludwig Institute for Cancer Research
Breast Cancer, Lung Cancer
Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older
Infections due to influenza and pneumococcus can be very serious and cause death. Anyone can get these infections. However, some people are at greater risk from the disease, including people 65 and older, the very young, and…
- Conditions
- Breast Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00741039
- Testing
- inactivated influenza vaccine and the 23- valent pneumococcal vaccine, inactivated influenza vaccine and the PPV23 vaccine (Pneumovax)
- Where
- United States
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)
The purpose of this study is to describe the 2 year progression-free survival in men with recurrent PSA-only disease after prostatectomy receiving combined enzalutamide and standard androgen-deprivation therapy (ADT) with salvage…
- Trial name
- STREAM (NCT02057939)
- Testing
- enzalutamide, Androgen Deprivation, Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Duke University
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
This phase II trial tests how well pertuzumab, trastuzumab, hyaluronidase-zzxf and enzalutamide works in treating patients with castration-resistant prostate cancer that has spread from where it first started to other places in…
- Trial name
- NCT05730712
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Mayo Clinic
Prostate Cancer
68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy
This study is being conducted to determine whether the combination of imaging agents 68-Ga RM2 and 68-Ga PMSA11 is better at assessing response to high intensity focused ultrasound (HIFU) or high dose rate (HDR) local therapy…
- Trial name
- NCT03949517
- Testing
- 68-Ga RM2, 68-Ga PSMA11, Investigational software and coils in PET/MR Scan
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Andrei Iagaru
Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
This phase II trial tests how well golimumab and apalutamide work in treating patients with castration resistant prostate cancer. Golimumab is in a class of medications called tumor necrosis factor (TNF) inhibitors.
- Conditions
- Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT05960578
- Testing
- Apalutamide, Biopsy, Biospecimen Collection
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Washington
Prostate Cancer
A Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGON
This study is a large observational study, set-up to observe how long-term treatment with FIRMAGON (hormone regulator) compare to other treatments in regards to cardiovascular events, changes in bone density, changes in blood…
- Trial name
- NCT01234350
- Where
- 160 sites in Belgium, Denmark and 13 more
- Volunteers
- 1,493 people
- Sponsor
- Ferring Pharmaceuticals
Metastatic Castration-resistant Prostate Cancer
Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)
The purpose of this study is to evaluate the efficacy and safety of olaparib versus enzalutamide or abiraterone acetate in subjects with metastatic castration-resistant prostate cancer who have failed prior treatment with a new…
- Trial name
- NCT02987543
- Testing
- olaparib, enzalutamide, abiraterone acetate
- Where
- 204 sites in United States, Argentina and 18 more
- Volunteers
- 387 people
- Sponsor
- AstraZeneca
Prostate Cancer Metastatic
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
The primary objective of the trial is to evaluate the clinical anti-tumor activity of EMD 525797 administered as 1-hour intravenous infusion every 3 weeks in terms of progression free survival (PFS) time in subjects with…
- Trial name
- PERSEUS (NCT01360840)
- Testing
- EMD 525797, Standard of Care (SoC)
- Where
- 71 sites in United States, Australia and 10 more
- Volunteers
- 180 people
- Sponsor
- EMD Serono
Prostate Cancer
Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer
RATIONALE: Giving samarium Sm 153 lexidronam pentasodium and 3-dimensional (3-D) conformal radiation therapy or intensity-modulated radiation therapy may keep prostate cancer from growing in patients with rising prostate-specific…
- Trial name
- NCT00551525
- Testing
- Radiotherapy, Samarium 153
- Where
- 29 sites in United States
- Volunteers
- 67 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
The purpose of this study is to determine the benefit of enzalutamide versus placebo as assessed by overall survival and progression-free survival in patients with progressive metastatic prostate cancer who have failed androgen…
- Trial name
- PREVAIL (NCT01212991)
- Testing
- Enzalutamide
- Where
- 269 sites in United States, Australia and 20 more
- Volunteers
- 1,717 people
- Sponsor
- Pfizer
Acute Myeloid Leukemia, Brain Glioblastoma
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
This randomized pilot clinical trial studies health care coach support in reducing acute care use and cost in patients with cancer.
- Conditions
- Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative, Extensive Stage Small Cell Lung Carcinoma
- Trial name
- NCT03154190
- Testing
- Best Practice, Laboratory Biomarker Analysis, Supportive Care
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- Stanford University
Prostate Cancer
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
The purpose of this phase 3B trial was to see how well a new trial drug (degarelix) works in terms of reducing the size of the prostate volume in prostate cancer patients who were scheduled to undergo subsequent radiotherapy for…
- Trial name
- NCT00833248
- Testing
- Degarelix, Goserelin, Bicalutamide
- Where
- 66 sites in United States, France and 5 more
- Volunteers
- 246 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
Evaluate Recovery of Testosterone for Patients Using Eligard
The purpose of this study is to determine if testosterone will recover to 90% by year 1 after using Eligard.
- Trial name
- Eligard (NCT01136226)
- Testing
- Eligard (TM)
- Volunteers
- 42 people
- Sponsor
- Chesapeake Urology Research Associates
Melanoma, Prostate Cancer
Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer
will scientifically evaluate whether Low Dose Naltrexone (LDN) has activity in refractory solid tumors within the context of a phase II clinical study
- Conditions
- Melanoma, Prostate Cancer, Renal Cancer
- Trial name
- NCT01650350
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Brown University
Prostate Cancer
GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer
Background: GE-148 (18F) is a new drug that is designed to attach to prostate cancer cells. Researchers are interested in combining the drug with a small amount of radioactive material to allow prostate cancer lesions to appear…
- Trial name
- NCT01176513
- Testing
- GE-148 (18F)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- GE Healthcare
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer
This phase I/II trial studies the side effects and best dose of calcitriol when given in combination with ketoconazole and therapeutic hydrocortisone and to see how well it works in treating patients with prostate cancer.
- Conditions
- Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage III Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT00536991
- Testing
- Calcitriol, Ketoconazole, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Roswell Park Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.